Increased Risk of Hemorrhagic and Ischemic Strokes in Patients with Splenic Injury and Splenectomy

Medicine (United States)

Volumn 94, Issue 35, 2015, Pages e1458-

  Lin, Jiun Nong ^a,b,c   Lin, Cheng Li ^b,d,h   Lin, Ming Chia ^b   Lai, Chung Hsu ⁱ   Lin, Hsi Hsun ^b   Yang, Chih Hui ^e,f   Kao, Chia Hung ^g  

^a Department of Internal Medicine ^*  (Taiwan)

^b Department of Internal Medicine   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d Management Office for Health Data   (Taiwan)

^e Department of Nuclear Medicine   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g Fu Jen Catholic Uiversity   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ MEIHO UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SPLEEN INJURY; SPLENECTOMY; STROKE PATIENT; ADVERSE EFFECTS; CASE CONTROL STUDY; CEREBRAL HEMORRHAGE; COMPLICATION; FACTUAL DATABASE; HEALTH INSURANCE; INJURIES; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SPLEEN; STATISTICS AND NUMERICAL DATA; STROKE; SURGERY; TAIWAN;

ADULT; AGED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SPLEEN; SPLENECTOMY; STROKE; TAIWAN;

EID: 84944894723     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001458     Document Type: Article

References (42)

1. Zonies D, Eastridge B. Combat management of splenic injury: trends during a decade of conflict. J Trauma Acute Care Surg. 2012;73:S71-74.
2. Cochran A, Mann NC, Dean JM, et al. Resource utilization and its management in splenic trauma. Am J Surg. 2004;187:713-719.
3. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114:2861-2868.
4. DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2007;165:1-209.
5. Rose AT, Newman MI, Debelak J, et al. The incidence of splenectomy is decreasing: lessons learned from trauma experience. Am Surg. 2000;66:481-486.
6. Rosati C, Ata A, Siskin GP, et al. Management of splenic trauma: a single institution's 8-year experience. Am J Surg. 2015;209:308-314.
7. Hommes M, Navsaria PH, Schipper IB, et al. Management of blunt liver trauma in 134 severely injured patients. Injury. 2015;46:837-842.
8. Kristinsson SY, Gridley G, Hoover RN, et al. Long-term risks after splenectomy among 8149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99:392-398.
9. Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43:182-186.
10. Stamou KM, Toutouzas KG, Kekis PB, et al. Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins. Arch Surg. 2006;141:663-669.
11. Jäis X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboem-bolic pulmonary hypertension. Thorax. 2005;60:1031-1034.
12. Dawson AA, Bennett B, Jones PF, et al. Thrombotic risks of staging laparotomy with splenectomy in Hodgkin's disease. Br J Surg. 1981;68:842-845.
13. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous throm-boembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467-473.
14. Skattum J, Naess PA, Gaarder C. Non-operative management and immune function after splenic injury. Br J Surg. 2012;99:59-65.
15. Borgna Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998;99:76-79.
16. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008;6:1289-1295.
17. Schilling RF. Spherocytosis, splenectomy, strokes, and heat attacks. Lancet. 1997;350:1677-1678.
18. Hathirat P, Mahaphan W, Chuansumrit A, et al. Platelet counts in thalassemic children before and after splenectomy. Southeast Asian J Trop Med Public Health. 1993;24(Suppl 1):213-215.
19. Boxer MA, Braun J, Ellman L. Thromboembolic risk of postsple-nectomy thrombocytosis. Arch Surg. 1978;113:808-809.
20. Visudhiphan S, Ketsa-Ard K, Piankijagum A, et al. Blood coagulation and platelet profiles in persistent post-splenectomy thrombocy-tosis. The relationship to thromboembolism. Biomed Pharmacother. 1985;39:264-271.
21. Troendle SB, Adix L, Crary SE, et al. Laboratory markers of thrombosis risk in children with hereditary spherocytosis. Pediatr Blood Cancer. 2007;49:781-785.
22. Goldfarb AW, Rachmilewitz EA, Eisenberg S. Abnormal low and high density lipoproteins in homozygous beta-thalassaemia. Br J Haematol. 1991;79:481-486.
23. Aviram M, Brook JG, Tatarsky I, et al. Increased low-density lipoprotein levels after splenectomy: a role for the spleen in cholesterol metabolism in myeloproliferative disorders. Am J Med Sci. 1986;291:25-28.
24. Rasouli J, Lekhraj R, Ozbalik M, et al. Brain-spleen inflammatory coupling: a literature review. Einstein J Biol Med. 2011;27:74-77.
25. Tuttolomondo A, Maida C, Pinto A. Inflammation and inflammatory cell recruitment in acute cerebrovascular diseases. Curr Immunol Rev. 2015;11:24-32.
26. Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Devel Ther. 2014;8:2221-2238.
27. Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol. 2011;165:243-250.
28. Sari TT, Gatot D, Akib AAP, et al. Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Medica Indones. 2014;46:217-225.
29. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87:779-789.
30. Tuttolomondo A, Pecoraro R, Casuccio A, et al. Peripheral frequency of CD4+ CD28-cells in acute ischemic stroke: relationship with stroke subtype and severity markers. Medicine. 2015;94:e813.
31. Urbanek C, Palm F, Buggle F, et al. Recent surgery or invasive procedures and the risk of stroke. Cerebrovasc Dis Basel Switz. 2014;38:370-376.
32. Wang T, Xu M, Ji L, et al. Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematol. 2006;115:39-45.
33. Korathanakhun P, Sathirapanya P, Geater SL, et al. Predictors of hospital outcome in patients with cerebral venous thrombosis. J Stroke Cerebrovasc Dis. 2014;23:2725-2729.
34. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008;26:871-895vii.
35. Pinto A, Tuttolomondo A, Di Raimondo D, et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism. 2008;57:676-682.
36. Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome. Atherosclerosis. 2012;225:216-219.
37. Tuttolomondo A, Pecoraro R, Di Raimondo D, et al. Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke with and without metabolic syndrome. Diabetol Metab Syndr. 2014;6:28.
38. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Effects of clinical and laboratory variables and of pretreatment with cardiovascular drugs in acute ischaemic stroke: a retrospective chart review from the GIFA study. Int J Cardiol. 2011;151:318-322.
39. Strano A, Hoppensteadt D, Walenga JM, et al. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost. 1996;22(Suppl 1): 35-40.
40. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke J Cereb Circ. 1993;24:35-41.
41. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236-242.
42. Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497, 180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Hae-most. 2012;108:225-235.